BIO (BioProtocol) fluctuates 41.0% in 24 hours: Driven by PEPTAIIgnitionSale oversubscription and trading volume surge
Bitget Pulse2026/05/02 13:35Volatility Brief
In the past 24 hours, BIO price rebounded from a low of $0.03964 to a high of $0.05590, currently trading at $0.05561, with an overall price swing of 41.0%. Trading volume has surged significantly, with a 24-hour turnover exceeding $45 million, at times reaching 25 times the average level; Open Interest (OI) has spiked 43.8%, and the funding rate has turned negative to -0.023%, indicating increasing pressure on shorts.
Brief Analysis of the Move
• Bio Protocol officially launched the PEPTAI Ignition Sale (AI agent project for peptide drugs), exceeding 5.9 times the subscription in just 30 minutes after going live, 20% of the supply was allocated to BIO stakers, incentivizing staking and USDC participation, thus driving active trading.
• Trading volume soared 207%, led by buying momentum (196K USDT within 15 minutes), with open interest rising in tandem. The negative funding rate intensified the short squeeze, resulting in a rapid price surge.
• The DeSci sector rotation has accelerated, while market attention grew due to the upgrade of BioXP and listing rumors on Upbit Korea, pushing turnover up to the $300 million level.
Market View and Outlook
The prevailing community sentiment is bullish, with long positions dominating on X, viewing the current situation as an opportunity for DeSci+AI biotech sector rotation. The target price is $0.048-$0.055, but the risk of a short-term squeeze is high (RSI at 78, indicating overbought conditions); analysts advise caution regarding a potential pullback to the $0.032-$0.037 support zone, and recommend monitoring the progress of the PEPTAI sale and staking data. If the price holds above $0.041, it is advised to maintain long positions.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for information purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Once the Federal Reserve starts the rate hike cycle, is "three consecutive hikes" a reasonable expectation?
BMO expects consecutive rate hikes in October and December, with a total of three increases potentially wiping out all rate cut gains for 2025. Vanguard believes "three consecutive hikes" is a reasonable starting point, but the actual number could be as high as six. There are historical exceptions: in 1997, the Federal Reserve raised rates only once and took no further action for the following 18 months. Meanwhile, trillion-dollar debt financing by AI giants, private credit exposure in the insurance industry, and the 10-year U.S. Treasury yield approaching 5% are the most dangerous pressure points in this rate hike cycle.
Goldman Sachs Also Changes Its Tune: The Fed Will Raise Interest Rates Next Week!
Goldman Sachs has shifted from predicting a rate hold to betting on a 25 basis point hike next week, stating that this change is not due to particularly bad inflation data—the August CPI was not perfect, but it wasn’t alarming either. The real key is that hawkish comments from Waller have already shaped market expectations: "If the inflation data isn’t perfect, there will be a rate hike." If the Federal Reserve backs down now, its credibility will suffer a serious blow and long-term interest rates could react sharply and immediately.
Meteora’s $20M fee surge fuels 18% rally – But MET’s next leg faces THIS hurdle
